Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLPP | Q16740 | 19/20 | 1.00 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.92 |
| ▸ | TCF7 | P36402 | 2/20 | 0.92 |
| ▸ | BCL9 | O00512 | 1/20 | 0.92 |
| ▸ | TCF4 | P15884 | 1/20 | 0.92 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.92 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15677334 | 1.00 | CLPP (1.00) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL15677335 | 0.96 | CLPP (1.00) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL20752946 | 0.96 | CLPP (0.92) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL178745 | 0.96 | CLPP (1.00) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL19833048 | 0.96 | CLPP (1.00) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL4865597 | 0.96 | CLPP (1.00) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL19833044 | 0.96 | CLPP (0.92) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL13744871 | 0.96 | CLPP (1.00) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL29352986 | 0.96 | CLPP (1.00) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL4865605 | 0.96 | CLPP (1.00) | CLPPCTNNB1TCF7BCL9TCF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11213527-B2 | Inhibitory effect of low molecular weight compound on cancer and fibrosis | NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY (JP) | 2022-01-04 | — | — | US | disclosed |
| US-20210386747-A1 | INHIBITORY EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS | KANONCURE, INC. (JP) | 2021-12-16 | — | — | US | disclosed |
| EP-3150207-A1 | INHIBITORY EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS | National University Corporation Tottori University (JP) | 2017-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11213527-B2 | Inhibitory effect of low molecular weight compound on cancer and fibrosis | MMP1, SERPINB1, LGALS1 | CLPP 4247/4885CTNNB1 481/4885TCF7 673/4885 |
| US-20210386747-A1 | INHIBITORY EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS | MMP1, SERPINB1, LGALS1 | CLPP 4247/4885CTNNB1 481/4885TCF7 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.